Zhitong Financial App News, Kangzhe Pharmaceutical (00867.HK) issued an announcement. Demei Pharmaceutical Co., Ltd. (Demei Pharmaceutical, an innovative pharmaceutical company specializing in skin health, is applying for independent listing on the main board of the Hong Kong Stock Exchange Limited), an innovative oral JAK1 inhibitor povorcitinib (proposed Chinese generic name: povorcitinib or product) (povorcitinib or product) has been approved by the China National Drug Administration (NMPA) Drug Evaluation Center for inclusion in the list of breakthrough treatment varieties The proposed indication is non-segmental vitiligo in adult patients. This certification is expected to speed up the development and review process of this product.

Zhitongcaijing · 1d ago
Zhitong Financial App News, Kangzhe Pharmaceutical (00867.HK) issued an announcement. Demei Pharmaceutical Co., Ltd. (Demei Pharmaceutical, an innovative pharmaceutical company specializing in skin health, is applying for independent listing on the main board of the Hong Kong Stock Exchange Limited), an innovative oral JAK1 inhibitor povorcitinib (proposed Chinese generic name: povorcitinib or product) (povorcitinib or product) has been approved by the China National Drug Administration (NMPA) Drug Evaluation Center for inclusion in the list of breakthrough treatment varieties The proposed indication is non-segmental vitiligo in adult patients. This certification is expected to speed up the development and review process of this product.